section name header

Pronunciation

pi-TAVa-sta-tin

Classifications

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: hmg coa reductase inhibitors (statins)

Indications

REMS


Livalo and Zypitamag

Livalo

Action

  • Inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme responsible for catalyzing an early step in cholesterol synthesis.
Therapeutic effects:
  • Lowers of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides;
  • Increases high-density lipoprotein cholesterol (HDL-C).

Pharmacokinetics

Absorption: Well absorbed (51%) following oral administration.

Distribution: Unknown.

Protein Binding: >99%.

Metabolism/Excretion: Mostly metabolized by the liver; 15% excreted in urine, 79% excreted in feces mostly as metabolites.

Half-Life: 12 hr.

Time/Action Profile

(effect on lipids)

ROUTEONSETPEAKDURATION
POwithin 4 wk4 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: pruritus, rash, urticaria

Endo: hyperglycemia

GI: constipation, diarrhea, liver enzymes

MS: back pain, extremity pain, myalgia, myositis, arthralgia, immune-mediated necrotizing myopathy, RHABDOMYOLYSIS

Neuro: amnesia, confusion, memory loss

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Primary Hyperlipidemia

Renal Impairment

Heterozygous Familial Hypercholesterolemia

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Livalo, Zypitamag